

# KEEPING KIDS IN TUNE



**Fennec Pharmaceuticals is a biotechnology company focused on the development of Sodium Thiosulfate for the prevention of platinum-induced chemotherapy hearing loss/ototoxicity in pediatric patients.**

## Investment Highlights

- ❖ US Orphan Drug Designation (7.5 years market exclusivity)
  - Potential for European Market Exclusivity for Pediatric Use (10 years)
- ❖ Completed enrollment of two Phase 3 trials
- ❖ COG Phase 3 trial achieved primary endpoint for hearing
  - Achieved primary efficacy endpoint of greater than 50% improvement in hearing
- ❖ SIOPEL 6 Phase 3 trial reported no difference in Event Free Survival and Overall Survival at 2 years for cisplatin vs. cisplatin + STS with no evidence of tumor protection
  - Efficacy results (primary endpoint of hearing loss) expected in 2017 when all children have reached 3.5 years of age
  - The interim results of the first 68 patients achieving centrally reviewed pure tone audiometry at or above 3.5 years of age were encouraging
- ❖ Significant unmet medical need with no approved treatment on market or in development
- ❖ Well positioned to initiate discussions with US & European regulators once hearing data is available from SIOPEL 6

## Recent News

- 6/6/16 SIOPEL 6 Study shows no difference in Event Free Survival and Overall Survival at 2 years for cisplatin vs. cisplatin + STS with no evidence of tumor protection
- 5/16/16 Fennec announces second closing USD\$5.0 million private placement of common shares by Essetifin (f/k/a Sigma Tau Finanziaria)
- 4/8/16 Fennec announces USD\$5.0 million private placement of common shares by Sigma Tau Finanziaria
- 12/9/15 Fennec announces new Chairman of the Board Khalid Islam
- 1/5/15 Fennec announces completion of patient enrollment in Sodium Thiosulfate Phase 3 SIOPEL 6 Study
- 12/3/14 Fennec announces USD\$2.2 million private placement
- 6/2/14 Fennec announces COG Study ACCL0431 Phase 3 Clinical Trial for Sodium Thiosulfate meets primary endpoint for prevention of cisplatin-induced hearing loss in children

## About the Company:

TSX .....	FRX
OTCQB .....	FENCF
Recent market price <sup>1</sup> .....	USD\$2.30
Shares Outstanding <sup>2</sup> .....	13.6
Market capitalization <sup>1</sup> .....	USD\$31.3
Cash <sup>2</sup> .....	USD\$5.5 million
Cash runway <sup>2</sup> .....	Q1 2018
Debt .....	\$0

<sup>1</sup> July 6, 2016

<sup>2</sup> Pro forma \$5.0 million investment by Sigma Tau

## Board of Directors

Dr. Khalid Islam

*Chairman of Board, Chairman and CEO at Gentium S.p.A. - sold to Jazz Pharma for \$1 billion*

Adrian Haigh

*Director, Currently SVP and General Manager PTC Therapeutics. Previously COO at Gentium S.p.A. - sold to Jazz Pharma for \$1 billion.*

Chris Rallis

*Director, Previously President & COO of Triangle Pharmaceuticals - sold to Gilead for \$500 million.*

Rosty Raykov

*CEO & Director, Fennec Pharma*

## CONTACT

Rosty Raykov

Chief Executive Officer

Fennec Pharmaceuticals

9196365144

[rroykov@fennecpharma.com](mailto:rroykov@fennecpharma.com)

[www.fennecpharma.com](http://www.fennecpharma.com)



FENNEC PHARMA